/AUTL
AUTL Stock - Autolus Therapeutics plc
Healthcare|BiotechnologyNASDAQ
$1.63+3.82%
+$0.06 (+3.82%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.59
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.40
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+461.3%upside
Target: $9.15
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AUTL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.61 – $1.65
TARGET (TP)$9.15
STOP LOSS$1.50
RISK/REWARD1:57.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.01
52W High$2.80
52W Low$1.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.12M | $1.70M | $6.19M | $1.51M | $1.72M |
| Gross Profit | $-130,900,000 | $1.70M | $6.19M | $1.51M | $-133,173,000 |
| Gross Margin | -1293.5% | 100.0% | 100.0% | 100.0% | -7765.2% |
| Operating Income | $-241,426,000 | $-179,701,000 | $-142,893,000 | $-140,374,000 | $-303,133,000 |
| Net Income | $-220,662,000 | $-208,383,000 | $-148,839,000 | $-142,096,000 | $-142,094,000 |
| Net Margin | -2180.5% | -12272.3% | -2403.0% | -9429.1% | -8285.4% |
| EPS | $-0.87 | $-1.20 | $-1.57 | $-1.97 | $-2.76 |
Company Overview
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 435.0% Upside
Now
$5
Low
$9
Average
$13
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 18th 2024 | Goldman | Upgrade | Buy | $7.6← $7 |
| November 15th 2024 | Redburn Atlantic | Upgrade | Buy | $13 |
| November 9th 2023 | Deutsche Bank | Initiation | Buy | $10 |
| March 27th 2023 | Wells Fargo | Resumed | Overweight | $8 |
| March 17th 2023 | Bryan Garnier | Initiation | Buy | $5 |
Earnings History & Surprises
AUTLBeat Rate
39%
Last 18 quarters
Avg Surprise
-10.9%
EPS vs Estimate
Beats / Misses
7/11
Last 12 quarters
Latest EPS
$-0.30
Q4 2025
EPS Surprise History
Q1 24
-69.2%
$-0.44vs$-0.26
Q2 24
-140.0%
$-0.24vs$-0.10
Q3 24
-15.8%
$-0.22vs$-0.19
Q4 24
-47.6%
$-0.31vs$-0.21
Q1 25
+57.1%
$-0.09vs$-0.21
Q2 25
-8.3%
$-0.26vs$-0.24
Q3 25
+25.0%
$-0.18vs$-0.24
Q4 25
-30.4%
$-0.30vs$-0.23
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.25 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.23 | $-0.30 | -30.4% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.24 | $-0.18 | +25.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.21 | $-0.09 | +57.1% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.21 | $-0.31 | -47.6% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.19 | $-0.22 | -15.8% | ✗ MISS |
Q2 2024 | May 17, 2024 | $-0.10 | $-0.24 | -140.0% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.26 | $-0.44 | -69.2% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.22 | $-0.26 | -18.2% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.28 | $-0.23 | +17.9% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $-0.31 | $-0.23 | +25.8% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.46 | $-0.47 | -2.2% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.42 | $-0.46 | -9.5% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.51 | $-0.41 | +19.6% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-0.49 | $-0.51 | -4.1% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.50 | $-0.47 | +6.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.50 | $-0.47 | +6.0% | ✓ BEAT |
Latest News
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
📈 PositiveBenzinga•Dec 12, 2025, 11:02 AM
Autolus Therapeutics Presents Prelim. Data From Ongoing Phase 1 CARLYSLE Trial In Patients With Severse Refractory Systemic Lupus Erythematosus
📈 PositiveBenzinga•Dec 8, 2025, 09:07 PM
Autolus' Obe-cel Shows 95.5% Response In Pediatric High-Risk r/r B-ALL With Low Severe CRS And ICANS At ASH 2025
📈 PositiveBenzinga•Dec 8, 2025, 01:38 PM
Autolus Therapeutics shares are trading higher after NICE issued draft guidance recommending AUCATZYL for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
📈 PositiveBenzinga•Nov 25, 2025, 05:22 PM
Autolus Wins UK Backing for New CAR-T Cancer Therapy AUCATZYL for Adults With Aggressive Leukemia
📈 PositiveBenzinga•Nov 25, 2025, 09:07 AM
Autolus Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 12, 2025, 01:48 PM
Autolus Therapeutics Q3 EPS $(0.30) Misses $(0.22) Estimate, Sales $21.194M Miss $21.311M Estimate
📉 NegativeBenzinga•Nov 12, 2025, 12:02 PM
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
📈 PositiveBenzinga•Nov 3, 2025, 05:14 PM
Autolus shares are trading higher after the company reported its drug Obe-cel showed an 83% remission rate in an early lupus study, with an FDA-backed Phase 2 trial planned next.
📈 PositiveBenzinga•Oct 27, 2025, 07:21 PM
Autolus' Obe-cel Shows 83% Remission Rate in Early Lupus Study, FDA-Backed Phase 2 Next
📈 PositiveBenzinga•Oct 27, 2025, 11:10 AM
Autolus Therapeutics Doses First Patient In Phase 1 BOBCAT Trial Evaluating Obe-Cel For Progressive Multiple Sclerosis
📈 PositiveBenzinga•Oct 20, 2025, 11:09 AM
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 09:41 AM
Autolus To Present Early Data From CARLYSLE Study Of Obe-cel In Severe Lupus At ACR Convergence 2025
➖ NeutralBenzinga•Sep 16, 2025, 12:19 PM
Frequently Asked Questions about AUTL
What is AUTL's current stock price?
Autolus Therapeutics plc (AUTL) is currently trading at $1.63 per share. The stock has moved +3.82% today.
What is the analyst price target for AUTL?
The average analyst price target for AUTL is $9.15, based on 1 analyst.
What sector is Autolus Therapeutics plc in?
Autolus Therapeutics plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AUTL's market cap?
Autolus Therapeutics plc has a market capitalization of $0.43 billion, making it a small-cap company.
Does AUTL pay dividends?
No, Autolus Therapeutics plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.73
Mkt Cap: $0.4B
ANNX
Annexon, Inc.
$5.17
Mkt Cap: $0.6B
AURA
Aura Biosciences, Inc.
$5.86
Mkt Cap: $0.4B
BNTC
Benitec Biopharma Inc.
$11.50
Mkt Cap: $0.3B
LBRX
LB Pharmaceuticals Inc Common Stock
$21.07
Mkt Cap: $0.5B
NMRA
Neumora Therapeutics, Inc. Common Stock
$1.75
Mkt Cap: $0.3B
QSI
Quantum-Si incorporated
$1.27
Mkt Cap: $0.2B
RAPT
RAPT Therapeutics, Inc.
$33.81
Mkt Cap: $0.6B
RCKT
Rocket Pharmaceuticals, Inc.
$3.23
Mkt Cap: $0.3B
SLDB
Solid Biosciences Inc.
$5.94
Mkt Cap: $0.5B
Explore stocks similar to AUTL for comparison